Business Standard

Dr Reddy's enters Rs 28,000 cr market with multiple sclerosis drug in US

The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement

reddy, dr reddy's
Premium

The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement.

Press Trust of India New Delhi
Dr Reddy's Laboratories on Saturday said it has launched Dimethyl Fumarate delayed-release capsules, used to treat multiple sclerosis (MS), in the US market.
The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement.
According to IQVIA Health data, the Tecfidera brand and generic market had sales of around $3.8 billion (about Rs 28,000 crore) in the US for the most recent twelve months ending in June 2020.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in